National Institute for Health and Care Excellence (NICE) criteria for initiation of GLP-1 and GIP analogues is as follows: if triple therapy with metformin and two other oral drugs is not effective, not tolerated or contraindicated, consider triple therapy by switching one drug for a GLP-1 analogues for adults with T2DM who have a body mass index (BMI) of 35kg/m 2 or higher[15]
Landlord may, in its discretion, allocate and assign parking passes among Tenant and the other tenants in the Building
Safety Considerations and Provider Evaluation Before Starting Before any GLP-1 dosing decision, a qualified provider should assess your full medical history, including kidney function, thyroid health, pancreatitis risk, and gastrointestinal conditions
Potential Side Effects and Considerations While CJC-1295 and Ipamorelin are generally well-tolerated, its important to be aware of potential side effects and considerations: Injection Site Reactions : Minor redness or irritation at the injection site may occur
LY3298176, a novel long-acting GIP/GLP-1 coagonist, shows enhanced activity on weight loss and energy utilization whilst maintaining its efficacy for glycaemic control
In recent years, the therapeutic footprint of this class has grown: long-acting agents (e.g., liraglutide, semaglutide) and next-generation dual/triple agonists (e.g., tirzepatide) have demonstrated superior glycemic control, weight reduction, and cardiovascular benefits in adults with T2DM (Yao et al., 2024)